Genetic Tools for Detecting VHF Bioweapons

用于检测甚高频生物武器的基因工具

• 批准号: 6562503
• 负责人: Brian L. Hjelle
• 金额: $ 22.5万
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6562503
• 关键词: Hantavirus; bioterrorism /chemical warfare; hemorrhagic fever; high throughput technology; monitoring device; technology /technique development; tissue /cell culture; transfection /expression vector

DESCRIPTION (provided by applicant): The recent deployment of a bioweapon in an attack on the citizens of the United States has moved bioterrorism from the realm of possible to actual threat. This new realization has brought the need for rapid, high-throughput diagnosis, treatment, and vaccination to the forefront. This application concentrates on development of high-throughput detection of live agents of viral hemorrhagic fever, using the highly lethal SNV (Bunyaviridae: Hantavirus) as the model organism. Furthermore, the technology we will develop under this funding will also be of considerable value as facilitating the advancement of treatments for hantavirus pulmonary syndrome (HPS), the disease associated with SNV. This application will develop reverse genetics technology for hantaviruses with the initial intent of preparation of cellular reporters that produce a green signal when the cells are exposed to live, replication-competent SNV. This development would have considerable potential for expanding the technology to other agents of viral hemorrhagic fever. We have a specific plan to further develop and commercialize the product after the initial development phase funded by this application and will seek further funding to develop basic information on the replication of hantaviruses at the end of the two-year funding cycle.

描述（由申请人提供）：在对美国公民的袭击中，最近部署了生物武器，将生物恐怖主义从可能的领域转移到了实际威胁。 这种新的认识使对快速，高通量诊断，治疗和疫苗接种的必要性进入了最前沿。 该应用集中于使用高致命的SNV（Bunyaviridae：Hantavirus）作为模型有机体的高通量检测病毒出血热的现场试剂。 此外，我们将在这笔资金下开发的技术也将具有相当大的价值，可以促进汉塔病毒肺综合症（HPS）的治疗方法，该疾病与SNV相关。 该应用将开发用于汉坦病毒的反向遗传技术，最初是在细胞暴露于活的，具有复制能力的SNV时制备细胞记者的目的。 这种发展将具有将技术扩展到其他病毒出血热的药物的巨大潜力。 在本申请资助的初始开发阶段之后，我们制定了一项特定计划，可以进一步开发和商业化产品，并将寻求进一步的资金，以在两年资金周期结束时开发有关汉坦病毒复制的基本信息。